Cantel Medical — Investor Presentation (January 2016)
31 slides from Cantel Medical's investor presentation, Jan 14, 2016
Slide 1: Forward Looking Statement
FORWARD LOOKING STATEMENT 2 This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words
Slide 2: Cantel Medical is a NYSE leader in Infection Prevention & Control
3 $582 Cantel Medical is a NYSE leader in Infection Prevention & Control (IP&C) MILLION1 1 Sales for the last twelve months ended October 31, 2015.
Slide 3: Sources of strength
~$6B Sources of strength 4 Leading pure-play in the growing $50B global IP&C market with existing businesses in addressable markets of Government / industry focus on IP&C is a growth driver, shielding our markets from weak economic cycles We lead Strong financial performance for more than Proven exp
Slide 4: Mission Statement
Mission Statement 5 Cantel Medical is dedicated to delivering innovative IP&C products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. 3 Understand customer needs and deliver novel solutions 4 Operate in teams with accountability and
Slide 5: 1,800 Global Employees and facility locations
1,800 Global Employees Cantel Medical Facilities 40 locations in North America Netherlands Singapore China United Kingdom Italy 6
Slide 6: Infection Prevention & Control Markets
Infection Prevention & Control Markets 7 80 million global procedures annually growing at an estimated 5% CAGR2 Colorectal cancer is a leading global cause of death 2 MILLION US HEALTHCARE ASSOCIATED INFECTIONS (HAIs) PER YEAR COST THE HEALTHCARE SYSTEM $33 BILLION ANNUALLY1 Endoscopy US ESRD patien
Slide 7: Leadership position in critical IP&C markets
Leadership position in critical IP&C markets 8 Endoscopy Automated endoscope reprocessing systems and procedural disposable products Water Purification & Filtration Water purification systems for dialysis facilities as well as sterilants and filtration products Healthcare Disposables Branded portfol
Slide 8: Three Synergistic Segments
Three Synergistic Segments 9 Endoscopy Water Purification & Filtration Healthcare Disposables Endoscopy Reprocessing & Procedure Room Products Medical & Life Science Water Purification & Filters Dental, Hospital, Sterility Assurance Chemistries, Manufacturing, Regulatory, R&D, HR, International Infr
Slide 9: Well-Balanced Portfolio: Three Major Segments
Well-Balanced Portfolio: Three Major Segments 10 Last 12 Months Ended October 31, 2015 Adjusted EBITDAS = $119M2,3 “All Other” includes Specialty Packaging Products. 1 Before allocation of corporate expenses of ~$19.8M. 2 Earnings before Interest, Taxes, Depreciation, Amortization, Stock compensatio
Slide 10: Long-term growth & margin expansion
Long-term growth & margin expansion 11 Strong cash flow funds acquisition program with modest leverage Adj. EBITDAS MARGIN CAGR: ’03-’15 16% 21% * FY’11 Net Debt includes $98M in debt assumed on the first day of fiscal year 2012 upon closing of the Byrne Medical acquisition. 1 Earnings before Intere
Slide 11: Sustainable growth strategy
Sustainable growth strategy 12 Market Expansion Strategic Acquisitions New Products CONTINUOUS IMPROVEMENT
Slide 12: Market expansion: Significant global investment in Sales & Marketing
Market expansion: Significant global investment in Sales & Marketing 13 Total S&M spending more than doubled over last 5 years Endoscopy expansion largely complete Water and HC disposable teams expanding Significant Growth of US Direct Sales Team Accelerating investments Go-direct in UK, Germany, It
Slide 13: New Products: Accelerated Investments in R&D Pipeline
New Products: Accelerated Investments in R&D Pipeline 14 Product development has grown by more than 2.5x over last 5 years Broadest range of endoscope reprocessors (AERs) Launching 3 new AER platforms Expanding procedural room product lines Endoscopy Portfolio Development of higher margin liquid che
Slide 14: Strategic acquisitions: Investing in all core segments & international capabilities
Strategic acquisitions: Investing in all core segments & international capabilities 15 Proven ability to integrate, leverage & grow acquired businesses Byrne Medical, PuriCore (UK), IMS (Italy), Medical Innovations (UK) New products, new markets, manufacturing expansion & international presence Endo
Slide 15: Long Term Growth Drivers: Endoscopy
Long Term Growth Drivers: Endoscopy 16 Colorectal cancer is a leading global cause of death, driving worldwide screening and treatment efforts Improved adenoma detection rates will accelerate colonoscopy procedures LARGE AND GROWING GLOBAL ADDRESSABLE MARKET TOTALING OVER $4 BILLION Single-shot AERs
Slide 16: Long Term Growth Drivers: Water Purification & Filtration
Long Term Growth Drivers: Water Purification & Filtration 17 End-Stage Renal Disease patient demographics drive de novo clinic build in the US Improved IP&C standards for dialysis patients, labor savings to facility operators Upgrade opportunity: 6,300+ US clinics today, majority use old technology
Slide 17: Long Term Growth Drivers: Healthcare Disposables
Long Term Growth Drivers: Healthcare Disposables 18 Sterility assurance category adds high-growth, higher-margin platform and call point in hospital channel Rapicide® OPA/28 launched in the United States, now launching in international markets DentaPure® Waterline Disinfection System adds new growth
Slide 18: Experienced executive team
Experienced executive team 19 Andrew A. Krakauer Chief Executive Officer Peter G. Clifford Exec. Vice President Chief Financial Officer Eric W. Nodiff Exec. Vice President General Counsel Steven C. Anaya Sr. Vice President Chief Accounting Officer Chris Geschickter Vice President Human Resources Gar
Slide 19: Historical P&L reveals success of growth programs
Historical P&L reveals success of growth programs 20 ($ in millions, except per share data) Fiscal Year Ending July 31, 2010 2011 2012 2013 2014 2015 CAGR: ’10 -’15 1Q’16 LTM4 Net Sales $274.0 $321.7 $386.5 $425.0 $488.7 $565.0 16% $153.8 $582.0 Gross Profit Gross Margin $111.0 40.5% $122.8 38.2% $1
Slide 20: Strong balance sheet & cash flow generation
Strong balance sheet & cash flow generation 21 ($ and shares in millions) Fiscal Year Ending July 31, 2007 2008 2009 2010 2011 2012 2013 2014 2015 1Q’16 Total Assets $263.7 $279.2 $277.9 $280.7 $321.4 $434.8 $487.7 $536.1 $584.0 $677.7 Current Ratio 2.1:1 2.2:1 2.3:1 2.3:1 2.6:1 2.4:1 2.5:1 2.5:1 2.
Slide 21: 5-Yr Strategic Plan: Double Sales & EPS from FY13 to FY18
5-Yr Strategic Plan: Double Sales & EPS from FY13 to FY18 Successfully completed year 1 and year 2 of plan Continued investments in high-growth, high-margin product lines Focus on channel expansion including international and hospital markets Execute proven acquisition program to accelerate global g
Slide 22: NYSE specialty IP&C leader
$582M NYSE specialty IP&C leader1 Strong, recession-buffered core business with high future growth prospects Excellent record with the FDA, EPA and global regulatory bodies Strong cash flow and balance sheet (1.0x leverage ratio3,4) Included in the S&P SmallCap 600® Index Forbes Best Small Companies
Slide 23: Cantel Medical: NYSE specialty IP&C leader
@ CANTEL MEDICAL $582M NYSE specialty IP&C leader* 73. 27 $0.12 recurring revenue and «cigs 7 $119M in LTM Adj successful acquisitions per share annual dividend EBITDAS223 . since 2000 (5 increases in 5 years) * Strong, recession-buffered core business with high future growth prospects * Excellent r
Slide 24: Medical Innovations
Medical Innovations 25 Purchase price of $79.6M in cash consideration For last twelve months ending June 30, 2015, MI had reported revenues and EBITDA of $28.5M and $7.6M1, respectively Transaction further enhances CMN’s position as leading provider of IP&C solutions in the Gastrointestinal endoscop
Slide 25: GAAP to Non-GAAP EPS reconciliation
GAAP to Non-GAAP EPS reconciliation 26 Fiscal Year Ending July 31, 2010 2011 2012 2013 2014 2015 1Q’16 LTM1 GAAP EPS2 $0.52 $0.52 $0.77 $0.95 $1.04 $1.15 $0.34 $1.23 + Intangible amortization $0.08 $0.10 $0.14 $0.16 $0.16 $0.21 $0.05 $0.21 + Acquisition related items $0.00 $0.02 ($0.02) ($0.02) $0.0
Slide 26: Net Income to Adjusted EBITDAS reconciliation
Net Income to Adjusted EBITDAS reconciliation 27 ($ in millions) Fiscal Year Ending July 31, 2007 2008 2009 2010 2011 2012 2013 2014 2015 1Q’16 LTM1 Net Income $8.1 $8.7 $15.6 $19.9 $20.4 $31.3 $39.2 $43.3 $48.0 $14.3 $51.0 + Income taxes 6.0 5.2 9.4 11.6 10.0 16.5 21.1 25.3 28.2 8.8 29.7 + Net Inte
Slide 27: Gross Debt to Net Debt reconciliation
Gross Debt to Net Debt reconciliation 28 ($ in millions) Fiscal Year Ending July 31, 2007 2008 2009 2010 20111 2012 2013 2014 2015 1Q’16 Gross Debt $57.0 $58.3 $43.3 $21.0 $122.0 $90.0 $95.0 $80.5 $78.5 $147.5 - Cash (15.9) (18.3) (23.4) (22.6) (18.4) (30.2) (34.1) (31.8) (31.7) (31.1) Net Debt $41.
Slide 28: GAAP to Non-GAAP EPS disclosure
GAAP to Non-GAAP EPS disclosure 29 Non-GAAP financial measures contained herein supplement information previously reported in filings on Form 10-Q and Form 10-K as well as in presentations by Company management to investors, analysts and others. The information below will not be deemed “filed” for p
Slide 29: GAAP to Non-GAAP EPS disclosure continued
GAAP to Non-GAAP EPS disclosure continued 30 Acquisition Related Items Since acquisition related items are atypical and often mask underlying operating performance, we excluded these amounts for purposes of calculating this non-GAAP financial measure to facilitate an evaluation of our current operat
Slide 30: GAAP to Non-GAAP EPS disclosure continued: EBITDAS and Adjusted EBITDAS
GAAP to Non-GAAP EPS disclosure continued 31 (b) EBITDAS and Adjusted EBITDAS The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and
Slide 31: GAAP to Non-GAAP EPS disclosure continued
GAAP to Non-GAAP EPS disclosure @ CANTEL MEDICAL continued. (b) EBITDAS and Adjusted EBITDAS The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to ac
Cantel Medical — Investor Presentation (January 2016) on 6ix